You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival

Article metrics

Article menu
Basic tumor immunology
Original research
Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival

 

Online download statistics by month:

Online download statistics by month: March 2023 to December 2025

AbstractFullPdf
Mar 2023399433169
Apr 202323224091
May 202311912548
Jun 2023787827
Jul 2023878829
Aug 202310710723
Sep 2023878928
Oct 2023768035
Nov 2023787823
Dec 2023758044
Jan 2024616139
Feb 2024545640
Mar 2024809080
Apr 2024526030
May 2024656936
Jun 2024707142
Jul 2024767936
Aug 2024433923
Sep 2024404428
Oct 2024576843
Nov 2024656827
Dec 2024909244
Jan 2025545738
Feb 2025737747
Mar 2025899139
Apr 202510110151
May 2025677025
Jun 2025333422
Jul 2025110
Dec 2025550
Total251426311207